PDF herunterladen
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(05): 390-395
DOI: 10.1055/s-0043-1774806
Original Article

A Pilot Study Conducted at a Tertiary Cancer Care Center, Evaluating the Serum Asparaginase Activity in Children Suffering from Acute Lymphoblastic Leukemia after the Administration of Biosimilar Pegaspargase

Authors

  • Archana Melavarige Venkatagiri 

    1   Department of Pediatric Hematology and Oncology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, India

  • Vasudeva K. Bhat 

    1   Department of Pediatric Hematology and Oncology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, India

  • Arjun Asok 

    2   Department of Biochemistry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, India

  • Krishnananda Prabhu 

    2   Department of Biochemistry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, India

Source of Funding None declared.
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints
Preview

Abstract

Introduction L-asparaginase is considered to be the most important component in the treatment of acute lymphoblastic leukemia (ALL). Intensifying the use of L-asparaginase during treatment for ALL has resulted in a significant rise in the percentage of children and adolescents who are cured of the disease. Asparaginase trough activity more than or equal to 100 IU/L on day 7 has been found to be the desired activity level in all childhood leukemia patients.

Objectives Due to the paucity of data on biosimilar pegaspargase in the upfront setting, we planned this prospective pilot study to evaluate the levels of serum asparaginase activity (SAA) after biosimilar pegaspargase infusion.

Materials and Methods It is a prospective, single-center, pilot study of 10 pediatric ALL patients for the duration of 6 months. All children less than 18 years with ALL on treatment with curative intent and receiving pegaspargase and who provided informed consent were included in this study. The enzymatic spectrophotometric method was used to determine SAA, and it was measured on the 7th and 14th days after the first dosage of pegaspargase-asparaginase, as well as on the 14th day after the second dose of pegaspargase-asparaginase, while toxicity was charted according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Results From 10 patients with a median age of 5.5 years, a grand total of 29 samples were taken for analysis. Children who received pegaspargase had either B-ALL or T-ALL. After the first dose, mean ± SD (standard deviation), SAA levels at day 7 was 131.3 ± 38 IU/L and at Day 14 was 94.8 ± 8 IU/L. After the second dose, mean ± SD SAA level at day 14 was 86.1 ± 15 IU/L. No patient had clinical hypersensitivity reaction and no patient reported any asparaginase-related toxicity. One patient died due to sepsis, infection with multidrug-resistant gram-negative bacteria.

Conclusions Biosimilar pegaspargase maintained good SAA levels 7 and 14 days after infusion.

Drug Trial Registration: Clinical Trial Registry of India vide reference CTRI/2021/08/036033 and available at https://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=59285&EncHid=&userName=

Keywords

pegaspargase - acute lymphoblastic leukemia - serum asparaginase activity - childhood leukemia

Note

The abstract of this text was published in the Supplementary issue: Abstracts of the 25th Annual Conference of the Pediatric Hematology Oncology chapter of the Indian Academy of Pediatrics (PHOCON 2022), N Delhi in November 2022 with doi: 10.1016/j.phoj.2022.10.176


The manuscript has been read and approved by all the authors, that the requirements for authorship (Pg. 18) have been met, and that each author believes that the manuscript represents honest work, if that information is not provided in another form.


Patient Consent

None declared.


Ethics Approval

This study was approved by Institutional Ethics Committee at Kasturba Hospital, Manipal and the procedures used in this study adhere to the tenets of the Declaration of Helsinki.


All procedures performed in studies involving human participants were in accordance with the ethical standards and by approval from the Kasturba Medical College and Kasturba Hospital Institutional Ethics Committee (DHR Registration No. EC/NEW/INST/2019/374, Dated 14th April 2021, IEC: 356/2021) and was registered at CTRI- REF/2021/08/046121. It was performed in line with the latest Helsinki Declaration's guiding principles from 2013.


Authors' Contributions

Vasudeva Bhat K conceptualized and designed the study. Archana M.V., Arjun Asok, and Krishnananda Prabhu helped in data acquisition and manuscript preparation.




Publikationsverlauf

Artikel online veröffentlicht:
18. September 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India